Paul Hillman
Clinical Genetics (M.D.) · Houston, TXNPI 1124405311
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Mirum Pharmaceuticals, Inc. accounts for 72.2% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $63,857, more than ten times the $98 reported in 2020.
Across 79 payments — averaging $866.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mirum Pharmaceuticals, Inc.$49K
- Chiesi USA, Inc.$10K
- Amicus Therapeutics, Inc.$4K
- Zevra Therapeutics Inc$3K
- Sanofi$972
- Biomarin Pharmaceutical Inc.$567
- plus $282 from 4 others
Across 20 payments — averaging $4301.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$36K
- AstraZeneca$27K
- Zevra Therapeutics Inc$23K
What the payments were for
- Consulting fees$38,37056%
- Speaking & faculty fees$10,70416%
- Travel & lodging$15,25122%
- Food & beverage$3,5075%
- Education$5841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mirum Pharmaceuticals, Inc. | 36 | $49,407 |
| Chiesi USA, Inc. | 12 | $10,059 |
| Amicus Therapeutics, Inc. | 2 | $3,679 |
| Zevra Therapeutics Inc | 3 | $3,450 |
| Sanofi | 12 | $972 |
| Biomarin Pharmaceutical Inc. | 9 | $567 |
| Ultragenyx Pharmaceutical Inc. | 2 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $67 |
| Cycle Pharmaceuticals Inc | 1 | $58 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (820) Cholbam$47,980
- CTEXLI$36,712
- ELFABRIO$7,478
- POMBILITI$3,648
- OPFOLDA$3,648
- Olpruva$3,402
- FERRIPROX$2,125
- Livmarli$1,193
- CEREZYME$247
- CERDELGA$247
- Palynziq$219
- (810) Chenodal$142
- NEXVIAZYME$112
How this compares
$68,416 in reported general payments places this provider in the 85th percentile of 37 clinical genetics (m.d.) providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ElapraseIdursulfase | 47 | $1,697,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Elaprase | $67 | $1,697,20747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 37 clinical genetics (m.d.) providers in Texas.
Other clinical genetics (m.d.) in Houston
- Hope NorthrupHouston$180K
- Brendan LeeHouston$28K
- David RodriguezHouston$28K
- Fernando ScagliaHouston$16K
- Claudia Soler-AlfonsoHouston$4K
- Andres Caceres SalgadoHouston$387
- Lilei ZhangHouston$193
- Laura FarachHouston$173
- Roni Zemet LazarHouston$172
- Lindsay BurrageHouston$23
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.